Feb 17, 2026 by Adam LevyIs Oracle a Once-in-a-Decade Buying Opportunity Right Now?The cloud computing competitor trades for a lower valuation than its bigger peers.
Feb 17, 2026 by Leo Sun2 Brilliant Energy Stocks to Buy Now and Hold for the Long TermGE Vernova and Cameco are evergreen energy plays.
Feb 17, 2026 by Anthony Di PizioShould You Buy the Vanguard S&P 500 ETF With the Stock Market Near a Record High? History Offers a Clear AnswerDespite recent volatility, trends like artificial intelligence could fuel another strong year for the stock market.
Feb 17, 2026 by Lawrence NgaCan AI Actually Improve Duolingo's Financials in 2026?Is Duolingo's AI investment strengthening its long-term earnings power or just adding excitement to the story?
Feb 17, 2026 by Eric VolkmanWhy Conagra Brands Stock Sank TodayThe company's latest business update didn't exactly inspire the market.
Feb 17, 2026 by Brett SchaferRestaurant Stocks See Traffic-Driven Rotation as Dining Patterns ShiftA closing gap in price is seeing customers switch from fast-casual to dine-in options while fast-food chains push heavy discounts.
Feb 17, 2026 by James Halley2 Monster Stocks to Hold for the Next 10 YearsCaterpillar and Okta benefit from the AI boom but have enough other revenue streams to balance out any boom-and-bust cycle.
Feb 17, 2026 by Jonathan PoncianoAgios Stock Down 16% in a Year as Fund Cuts Stake by $5.6 Million After 50% November CrashAgios Pharmaceuticals targets rare blood disorders with a marketed anemia drug and a focused clinical-stage pipeline.
Feb 17, 2026 by Will HealyAmazon Is Working On an AI Content Marketplace for Publishers. Could This Move Send the Stock Soaring?Amazon's size likely influences how much effect this business will have on the company.
Feb 17, 2026 by Patrick SandersHow This Global Small Cap ETF Fits Into a Long-Term StrategyYou get instant diversification and a solid dividend, too.
Feb 17, 2026 by Jonathan PoncianoCogent Biosciences Stock Soars 346% in a Year, but One Fund Just Sold Off $4.5 MillionThis biotech firm develops precision therapies targeting rare genetic diseases, with a lead candidate focused on oncology indications.
Feb 17, 2026 by Eric VolkmanWhy Alnylam Pharmaceuticals Stock Was Soaring on MondayOne pundit tracking the company upgraded his recommendation.
Feb 17, 2026 by Daniel SparksIs Salesforce Stock a Buy After Falling 30% This Year?The software-as-a-service stock has been hammered amid investor concerns about the disruptive potential of AI. But could AI actually be a catalyst for Salesforce?
Feb 17, 2026 by Jonathan PoncianoStructure Therapeutics Stock Up 187% in One Year as Fund Trims $8 Million From StakeStructure Therapeutics develops oral therapies for chronic diseases, using a proprietary platform to target G-protein-coupled receptors.
Feb 17, 2026 by Jonathan PoncianoKymera Therapeutics Stock Up 120% in 1 Year as Fund Adds $3 Million MoreKymera Therapeutics develops targeted protein degradation therapies for immunology and oncology, advancing multiple clinical-stage programs.
Feb 17, 2026 by Steven PorrelloShould You Buy the Dip on Oklo?Oklo is down about 15% in 2026. Is now the time to buy?
Feb 17, 2026 by Matt DiLalloHow to Earn $500 a Month From Energy Transfer StockEnergy Transfer is an income-producing machine.
Feb 17, 2026 by Brett SchaferThe Smartest Growth Stocks to Buy With $100 Right NowThese two businesses have durable growth characteristics and should perform well over the next five years.
Feb 17, 2026 by John BallardArena Capital Sells $35 Million of Diebold Nixdorf StockDiebold Nixdorf supplies automation and digital solutions for banks and retailers, spanning hardware, software, and managed services.
Feb 17, 2026 by Anders Bylund1 AI Stock That Could Turn $100 Per Month Into $27,675You don't need a fortune to build one. You just need time and consistency.
